Milrinone acts as a selective phosphodiesterase 3 (PDE3) inhibitor [1]. By inhibiting PDE3, milrinone increases intracellular cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular smooth muscle cells [1][2]. This elevation of cAMP leads to a positive inotropic effect on the heart and vasodilation [1]. The increased cAMP in cardiac muscle enhances calcium influx, which strengthens myocardial contraction [2]. In vascular smooth muscle, higher cAMP levels promote relaxation, resulting in decreased systemic vascular resistance [2].
How does milrinone work in the body?
Milrinone's mechanism of action specifically targets phosphodiesterase 3 (PDE3). PDE3 is an enzyme responsible for breaking down cyclic adenosine monophosphate (cAMP) [1]. When milrinone inhibits PDE3, it prevents the breakdown of cAMP, leading to higher concentrations of cAMP within cells [1][2]. In the heart, elevated cAMP amplifies the effects of calcium, making the heart muscle contract more forcefully. In blood vessels, increased cAMP causes the smooth muscles to relax, widening the vessels [2]. This dual action makes milrinone effective in treating certain types of heart failure by improving the heart's pumping ability and reducing the workload on the heart [2].
What are the effects of milrinone on the heart?
Milrinone increases the force of myocardial contraction, a process known as positive inotropy [1]. This effect is achieved by increasing intracellular cAMP levels in cardiac myocytes, which in turn enhances calcium availability for excitation-contraction coupling [2]. Consequently, the heart pumps blood more effectively.
What are the effects of milrinone on blood vessels?
Milrinone causes vasodilation, meaning it widens blood vessels [1]. This occurs due to increased cAMP levels in vascular smooth muscle cells, which promotes relaxation [2]. The resulting decrease in systemic vascular resistance reduces the pressure against which the heart has to pump, thereby decreasing the heart's workload [2].
When might milrinone be prescribed?
Milrinone is typically used for short-term management of acute decompensated heart failure [2]. It is often considered when patients do not respond adequately to other treatments, such as diuretics, beta-blockers, and ACE inhibitors [2]. Its ability to improve cardiac output and reduce vascular resistance makes it valuable in situations where the heart is struggling to pump blood efficiently.
Are there alternatives to milrinone for heart failure?
Other medications used in the management of heart failure include diuretics to remove excess fluid, ACE inhibitors and angiotensin II receptor blockers (ARBs) to lower blood pressure and reduce cardiac workload, and beta-blockers to slow heart rate and reduce the heart's oxygen demand [3]. In some cases, other inotropic agents might be considered, though their mechanisms and side effect profiles can differ [2][3].
How is milrinone administered?
Milrinone is administered intravenously, usually as a continuous infusion [2]. This method allows for precise control of drug levels and rapid titration to achieve the desired therapeutic effect in acutely ill patients [2].
What are potential side effects of milrinone?
Common side effects of milrinone include arrhythmias, such as ventricular tachycardia, and hypotension [2]. Other potential adverse effects can involve gastrointestinal issues like nausea and vomiting [2]. Careful monitoring of heart rhythm and blood pressure is essential during treatment [2].
What is the difference between milrinone and other inotropes?
Unlike digoxin, which acts on the sodium-potassium pump to indirectly increase intracellular calcium, milrinone directly increases cAMP via PDE3 inhibition [1][4]. Dobutamine, another inotrope, is a beta-adrenergic agonist that stimulates beta-1 receptors in the heart [4]. Milrinone's unique mechanism results in both inotropic and vasodilatory effects, whereas dobutamine primarily increases contractility with some vasodilatory properties, and digoxin's effects are more complex and slower to onset [1][4].
What is the drug class of milrinone?
Milrinone is classified as a phosphodiesterase 3 (PDE3) inhibitor [1]. This classification highlights its specific molecular target and mechanism of action in treating cardiovascular conditions.
What is the active ingredient in milrinone?
The active ingredient in milrinone is milrinone itself [1]. It is a bipyridine derivative [1].
What is the brand name for milrinone?
Milrinone is available under the brand name Primacor [2].
---
Sources:
[1] https://www.drugpatentwatch.com/en/drug/milrinone
[2] https://www.medicinenet.com/milrinone/article.htm
[3] https://www.drugpatentwatch.com/en/drug/sacubitril-valsartan
[4] https://www.drugpatentwatch.com/en/drug/digoxin